Alder Biopharmaceuticals, Inc. (ALDR)’s Trend Up, Especially After Today’s Strong Session

December 7, 2017 - By Marguerite Chambers

The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) is a huge mover today! The stock increased 5.29% or $0.55 during the last trading session, reaching $10.95. About 472,741 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 33.67% since December 7, 2016 and is downtrending. It has underperformed by 50.37% the S&P500.
The move comes after 7 months positive chart setup for the $741.98M company. It was reported on Dec, 7 by We have $11.39 PT which if reached, will make NASDAQ:ALDR worth $29.68 million more.

Analysts await Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report earnings on February, 22. They expect $-1.10 earnings per share, down 13.40 % or $0.13 from last year’s $-0.97 per share. After $-0.92 actual earnings per share reported by Alder Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 19.57 % negative EPS growth.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. Therefore 88% are positive. Alder Biopharmaceuticals had 28 analyst reports since August 6, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of ALDR in report on Wednesday, August 9 with “Outperform” rating. As per Tuesday, March 29, the company rating was maintained by Credit Suisse. The firm has “Hold” rating by Credit Suisse given on Wednesday, June 28. The firm has “Outperform” rating given on Thursday, April 21 by Wells Fargo. The firm has “Buy” rating by Aegis Capital given on Thursday, June 29. Credit Suisse maintained it with “Hold” rating and $11.0 target in Thursday, August 24 report. Needham maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) on Tuesday, June 27 with “Buy” rating. Jefferies maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) on Wednesday, July 27 with “Buy” rating. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by Needham on Thursday, June 8. The company was initiated on Wednesday, April 20 by Brean Capital.

More news for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were recently published by:, which released: “Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare …” on November 22, 2017.‘s article titled: “Why Alder Biopharmaceuticals Inc Is Sinking Today” and published on July 12, 2017 is yet another important article.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $741.98 million. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: